ANI Pharmaceuticals Overview
Update this profile
Share Price
$35.84
(As of Thursday Closing)
ANI Pharmaceuticals General Information
Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
ANI Pharmaceuticals Stock Performance
(As of Thursday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$35.84
$35.87
$22.31 - $60.23
$625M
17.4M
97.6K
-$4.30
ANI Pharmaceuticals Financials Summary
In Thousands, USD
TTM
30-Jun-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
746,487
958,187
528,619
871,921
Revenue
251,322
216,136
208,475
206,547
EBITDA
(8,718)
3,164
28,190
60,735
Net Income
(63,636)
(42,603)
(22,548)
6,094
Total Assets
751,334
771,598
461,190
456,789
Total Debt
286,945
287,370
185,686
185,749
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ANI Pharmaceuticals Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore ANI Pharmaceuticals‘s full profile, request access.
Request a free trial
ANI Pharmaceuticals Comparisons
Description
Primary Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid
Pharmaceuticals
Baudette, MN
601
As of 2021
00000
000000000
00000
do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
000000000000000
Haifa Bay, Israel
0000
As of 0000
0000
0.000
0000-00-00
00000000000
lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
000000000000000
Trevose, PA
000
As of 0000
000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial
ANI Pharmaceuticals Competitors (12)
Company Name
Financing Status
Location
Employees
Total Raised
Last Financing Date/Type
Last Financing Amount
Taro Pharmaceutical Industries
Corporate Backed or Acquired
Haifa Bay, Israel
0000
0000
00000000000
0000000 0000000
Corporation
Trevose, PA
000
000000000
000000000000000 00
Corporation
Lagos, Nigeria
00
000000 00000000000
Formerly PE-Backed
Bridgewater, NJ
0000
00.000
000000 - 000
00.000
000000000000
Corporation
Staines-Upon-Thames, United Kingdom
0000
00.00
0000000000.
You’re viewing 5 of 12 competitors. Get the full list »
ANI Pharmaceuticals Patents
6
Total Documents
Applications and Grants
000
Total Patents
Families
000
Granted
000
Pending
000
Expiring
in next 12 mo
ANI Pharmaceuticals Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
US-20120046264-A1
Commercial scale production methods for transdermal hormone formulations
Abandoned
17-Aug-2010
0000000000
US-20170232002-A1
Commercial scale production methods for transdermal hormone formulations
Abandoned
17-Aug-2010
0000000000
US-20120022033-A1
Methods for decreasing cardiovascular risk in postmenopausal women
Abandoned
23-Jul-2010
0000000000
US-20170128462-A1
Methods for treating female sexual dysfunction while decreasing cardiovascular risk
Abandoned
02-Jul-2010
0000000000
US-20120004204-A1
Methods for treating sexual dysfunction while decreasing cardiovascular risk
Abandoned
02-Jul-2010
A61K31/568
To view ANI Pharmaceuticals’s complete patent history, request access »
ANI Pharmaceuticals Executive Team (17)
Update this profile
Name
Title
Board Seat
Contact Info
Nikhil Lalwani
Chief Executive Officer & Board Member
Stephen Carey
Senior Vice President and Chief Financial Officer
Muthusamy Shanmugam
Chief Operating Officer, Operations & Board Member
Christopher Mutz
Executive
Brian McCrudden
Senior Director of Business Development
You’re viewing 5 of 17 executive team members. Get the full list »
ANI Pharmaceuticals Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
ANI Pharmaceuticals Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore ANI Pharmaceuticals‘s full profile, request access.
Request a free trial
ANI Pharmaceuticals
Investments & Acquisitions (25)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
000000 000000
28-Jun-2022
000000000
Buildings and Property
000000 00
00000000 0000
19-Nov-2021
0000000000
00000
Pharmaceuticals
000000 00
000000 (0 000
06-Apr-2021
000000000
Buildings and Property
000000 00
000 000000000
01-Jul-2020
000000000
000
Buildings and Property
Amerigen Pharmaceuticals
09-Jan-2020
Merger/Acquisition
000.00
Pharmaceuticals
000000 00
You’re viewing 5 of 25 investments and acquisitions. Get the full list »